Peer-reviewed journal articles featuring Fortrea oncologists published 2020-2026

Fortrea is proud to support our sponsors with a team of over 50 oncologists committed to navigating the complexities of oncology clinical research and maximizing the impact of their product to the current global therapeutic landscape. With support spanning translational research and early phase development through product launch and post-marketing studies, our team members help guide clinical development planning, establish target product profiles, perform feasibility and risk assessment and provide program-level medical oversight. This collaborative approach can result in co-authorship of peer-reviewed journal articles based on projects we've supported. They also have contributed to industry knowledge via articles about their own collaborative and academic work.

Fortrea

2026	
Number	**Authors, Title, Journal**
2026.1	Berardi R, Bruschi G, Paoloni F, Pecci F, Tola E, Cognigni V, Galassi T, Borgheresi A, Cantini L, Santamaria L, Gualtieri M, Lunerti V, Chiodi N, Agostinelli V, Di Pietro Paolo M, Sbrollini A, Agostini A, Mentrasti G, Ficarra S, Mazzaschi G, Parisi A, Giampieri R, Saini KS, Buti S, Tiseo M,Vignini A, Giovagnoni A, Burattini L. **Clinically interpretable nomogram combining body composition and clinicopathological features for one year survival prediction in advanced solid tumors.** *Scientific Reports.* February 2026. https://www.nature.com/articles/s41598-026-37510-1
2026.2	Beaumont H, Cantini L, Saini KS, Faye N, Gill R, Iannessi A. **What are RECIST 1.1 progressions made of? Variability in double-read oncology trials.** *Eur Radiol*. February 2026. https://doi.org/10.1007/s00330-025-12234-4
2026.3	Arecco L, Cacilhas PM, Lara Gismondi CB, Bruzzone M, Gentile G, Gerosa R, Blondeaux E, Agostinetto E, Dauccia C, Lobo-Martins S, Grochot R, Saini KS, Azim Jr. HA, Debiasi M, De Caluwé A, Buisseret L, Del Mastro L, Lambertinia M, de Azambuja E. **Association between alcohol consumption and breast cancer incidence and prognosis: A systematic review and meta-analysis.** *The Breast.* February 2026. https://doi.org/10.1016/j.breast.2026.104719
2026.4	Saini KS, Koopman M, Martins-Branco D, Bossi P, Winther SB, Brahmi M, Braña I, Calvo E, Castelo-Branco L, Colombo I, de Azambuja E, de Ruysscher D, Dienstmann R, Dingemans AMC, Ekholm M, Gallois C, Golfinopoulos V, Grande E, Halabi S, Rhun EL, Saux OL, Leighl NB, Lonardi S, Lorenzen S, Lorusso D, Minniti G, Mountzios G, Oldenburg J, Oosting SF, Osterlund P, Perez-Gracia JL, Pellat A, Piperno-Neumann S, Plummer R, Porta C, Punie K, Ray-Coquard I, Remon J, Ruhlmann CH, Rutkowski P, Siu LL, Stacchiotti S, Suarez C, Suijkerbuijk K, Taieb J, Trapani D, Valachis A, van Laarhoven HWM, Vogel A, Zer A, Pentheroudakis G, Delaloge S, Twelves C. **ESMO Adaptation of Lines of Systemic Therapy (EnLiST): A consensus framework for standardising the designation of lines of therapy in solid tumours.** *Annals of Oncology.* February 2026. https://www.annalsofoncology.org/article/S0923-7534%2826%2900064-5/fulltext
2026.5	Heras BDL, Oelke C, Atwell P, Herrero H, Nunes P, Saini KS, Boixader LV, Laing C, Bush J, Calvo E. **Human absorption, metabolism and excretion (hAME) mass balance studies in patients with cancer.** *Clinical and Translational Science.* June 2026. https://doi.org/10.1111/cts.70620
2026.6	Strickland KC, Wallen ZD, Pabla S, Ko HC, Previs RA, Green MF, Hastings S, Dillard A, Sathyan P, Saini KS, Jensen TJ, Caveney BJ, Eisenberg M, Ramkissoon S, Severson EA. **Machine learning algorithm for the detection of tumor microsatellite instability based on multiomics biomarkers.** *JCO Clinical Cancer Informatics.* June 2026. https://ascopubs.org/doi/10.1200/CCI-25-00367
2026.7	Czajka-Francuz P, Twelves C, Spicer J, Munje A, Vidal L, Plummer R, Mistry D, Novikov M, Bush J, Srinivasan G, Das S, Sandhu S, Bohra V, Joshi C, Morrison K, Chavan S, Thistlethwaite F, Walding A, Clack G, George M, Sarker D, Ali R, Blagden SP, Evans TRJ, Saini KS. **Oncology drug development in the UK: Analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.** *British Journal of Cancer.* July 2026. https://doi.org/10.1038/s41416-026-03543-6
2026.8	Garcia Requesens M, Mankan AK, Cantini L, Calabresi M, Vidal L, Brown J, Lang S, Kaura B, Veselkov K, Xenarios I, Saini KS. **Role of health digital twins in oncology drug development: A primer.** *Frontiers in Oncology.* August 2026. https://pubmed.ncbi.nlm.nih.gov/42707983/

Full list of published journals continued:

Number	Authors, Title, Journal
2026.9	Jiang H, Niccob J, Soo-Chin L, Tse G, Park H, Saini KS, Shapiro MD, Ng M, Dalakoti M. **Trends, burden and overlaps in risk factors between cardiovascular disease and neoplasms in Asia: A global burden of disease analysis.** *JACC CardioOncology.* September 2026.
2026.10	Nogueira A, Brondon J, Haradinov K, Gopalakrishnan S, Huang K, Mukherjee D, Agarwal S, Strickland KC, Vidal L, Joshi C, Brookes R, Prasad R, Das S, Mankan AK, Munje A, de Las Heras B, Singh BP, Gandia D, Ramkissoon S, Raza FS, Chico I, Prasad SK, Perez J, Prasad A, Sarker D, Taieb J, Saini KS. **Early-onset colorectal cancer: Clinical and molecular features with emerging insights from comprehensive genomic profiling.** *Oncology and Therapy.* September 2026. https://link.springer.com/article/10.1007/s40487-026-00467-2
2026.11	Ghirardi MP, Brandalise P, Berrondo M, Leáo D, Pericole F, Magalháes Filho RJP, Crusoé E, Maiolino A, Hungria VTM, Saini KS, da Cuhna Junior AD. **Dysregulation of the bone marrow immune microenvironment and clinical outcomes in multiple myeloma.** *Immuno.* https://www.mdpi.com/2673-5601/6/4/66

2025	
Number	**Authors, Title, Journal**
2025.1	Cortellini A, Brunetti L, Di Fazio GR, Garbo E, Pinato DJ, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Awad M, Alessi JV, Montrone M, Owen DH, Signorelli D, Fidler MJ, Li M, Camerini A, De Giglio A, Young L, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, Awosika NO, Napolitano A, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Newsom-Davis T, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Pantano F, Morabito A, Leonetti A, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Bell J, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Rogado J, Moliner L, Biello F, Aboubakar Nana F, Dingemans AM, Aerts J, Ferrara R, Torri V, Abu Hejleh T, Takada K, Naqash AR, Garassino M, Peters S, Wakelee H, Nassar AH, Ricciuti B. **Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials: Results from the Pembro-real 5Y global registry.** *Journal for ImmunoTherapy of Cancer.* February 2025. https://jitc.bmj.com/content/13/2/e010674.long
2025.2	Besliu C, Tanase AD, Rotaru I, Espinoza J, Vidal L, Poelman M, Juan M, Fernández de Larrea C, Saini KS. **The evolving landscape in multiple myeloma: From risk stratification to T cell-directed advanced therapies.** *MDPI.* February 2025. https://www.mdpi.com/2072-6694/17/3/525
2025.3	Hamilton EP, Loibl S, Bachelot T, Gnant M, Niikura N, Park YH, Tolaney SM, Pistilli B, Rastogi P, Saini KS, Gioni I, Johnston S, Nunes R, Quintana A, Stuart M, Syta E, Walding A, Klinowska T, Mayer IA. **CAMBRIA-1 & CAMBRIA-2 Phase III trials: Camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.** *Future Oncology.* February 2025. https://doi.org/10.1080/14796694.2025.2459548
2025.4	Pecci F, Cognigni V, Giudice GC, Paoloni F, Cantini L, Saini KS, Abushukair HM, Naqash AR, Cortellini A, Mazzaschi G, Alia S, Membrino V, Arandi E, Tiseo M, Buti S, Vignini A, Berardi R. **Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review.** *Critical Reviews in Oncology/Hematology.* May 2025. https://www.sciencedirect.com/science/article/abs/pii/S1040842825000423
2025.5	Green MF, Wallen ZD, Ko HC, Strickland KC, Dillard A, Conroy JM, Dash DP, Nesline MK, DePietro P, Zhang S, Saini KS, Sathyan P, Eisenberg M, Caveney B, Ramkissoon S, Severson EA, Previs RA. **Utilization of a multi-modal comprehensive genomic and immune profiling testing strategy results in a high rate of test success and detection of clinically relevant biomarkers while optimizing tissue usage.** *Molecular Diagnosis & Therapy.* June 2025. https://pubmed.ncbi.nlm.nih.gov/40482003

Full list of published journals continued:

Number	Authors, Title, Journal
2025.6	Batra U, Sharma M, Miller AA, Chufal KS, Ahmad I, Dewan A, Chowdhary S, Amrith BP, Sachdeva R, Batra V, Umesh P, Bhatia K, Nathany S, Mehta A, Filho PN, Tolba K, Chico IM, Boixader LV, Cantini L, Saini KS. **First-line pembrolizumab for metastatic NSCLC in lower middle-income countries: Bridging the efficacy-effectiveness gap.** *Immunotherapy.* September 2025. https://pubmed.ncbi.nlm.nih.gov/40910565/
2025.7	Cortellini A, Santo V, Brunetti L, Garbo E, Pinato DJ, La Cava G, Naidoo J, Katz A, Loza M, Neal JW, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Alessi JV, Montrone M, Owen DH, Ramella S, Signorelli D, Fidler MJ, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Passiglia F, Yendamuri S, Guida A, Ghidini M, D'Alessio A, Banna GL, Fulgenzi CAM, Grisanti S, Grossi F, D'Incecco A, Josephides E, Van Hemelrijck M, Russo A, Gelibter A, Spinelli G, Verrico M, Tomasik B, Giusti R, Balachandran K, Bria E, Sebastian M, Rost M, Forster M, Mukherjee U, Landi L, Mazzoni F, Aujayeb A, Dupont M, Curioni-Fontecedro A, Chiari R, Sforza V, Tiseo M, Friedlaender A, Addeo A, Zoratto F, De Tursi M, Cantini L, Roca E, Mountzios G, Rocco D, Della Gravara L, Kalvapudi S, Inno A, Bironzo P, Di Marco Barros R, O'Reilly D, Fitzpatrick O, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Piedra A, Agustoni F, Cortinovis DL, Tonini G, Minuti G, Bennati C, Mezquita L, Gorría T, Servetto A, Beninato T, Lo Russo G, Prelaj A, De Giglio A, Rogado J, Moliner L, Nadal E, Biello F, Aboubakar Nana F, Dingemans AM, Aerts JGJV, Ferrara R, Abu Hejleh T, Takada K, Naqash AR, Garassino MC, Peters S, Wakelee HA, Nassar AH, Ricciuti B, Soda P, Caruso CM, Guarrasi V. **Transformer-based AI approach to unravel long-term, time-dependent prognostic complexity in patients with advanced NSCLC and PD-L1 ≥50%: Insights from the pembrolizumab 5-year global registry.** *Journal for ImmunoTherapy of Cancer.* September 2025. https://jitc.bmj.com/content/13/9/e012423
2025.8	Batra U, Sharma M, Ahmad I, Rajappa S, Nathany S, Cantini L, Sachdeva R, Batra V, Choudhury R, Agarwal B, Dewan A, Choudhary S, Amrith BP, Darlong LM, Chufal KS, Umesh P, Bhatia K, Filho PN, Saini KS, Mehta A. **A decade of treating ALK-rearranged non-small cell lung cancer in a lower middle-income country: Changing patterns and improving survival.** *Oncology & Therapy.* October 2025. https://link.springer.com/article/10.1007/s40487-025-00390-y
2025.9	Da Cunha ADJ, Carrilho LAO, Nunes Filho PRS, Cantini L, Vidal L, Mendes MCS, Carvalheira JBC, Saini KS. **The role of metabolic inflammation and insulin resistance in obesity-associated carcinogenesis.** *Onco.* October 2025. https://www.mdpi.com/2673-7523/5/4/47
2025.10	Cortellini A, Garbo E, La Cava G, Citarella F, Santo V, Brunetti L, Pinato DJ, Naidoo J, Loza M, Genova C, Gettinger S, Kim SY, Jayakrishnan R, El Zarif T, Russano M, Pecci F, Di Federico A, Montrone M, Owen DH, Signorelli D, Li M, Camerini A, Halmos B, Vincenzi B, Metro G, Yendamuri S, Grossi F, Josephides E, Tomasik B, Giusti R, Bria E, Sebastian M, Rost M, Acker F, Landi L, Mazzoni F, Morabito A, Leonetti A, Cantini L, Mountzios G, Kalvapudi S, O'Reilly D, Karapanagiotou E, Monnet I, Baena J, Macerelli M, Majem M, Piedra A, Cortinovis DL, Tonini G, Minuti G, Mezquita L, Gorria T, Beninato T, Lo Russo G, PrelaJ A, De Giglio A, Biello F, Aboubakar Nana F, Dingemans AMC, Aerts JG, Ferrara R, Hejleh TA, Takada K, Naqash AR, Garassino MC, Wakelee HA, Nassar A, Ricciuti B, Soda P, Caruso CM, Guarrasi V. **Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50% and poor performance status: Transformer-based AI to characterize prognostic complexity.** *Lung Cancer.* November 2025. https://www.lungcancerjournal.info/article/S0169-5002(2500691-9/fulltext

Full list of published journals continued:

2024	
Number	**Authors, Title, Journal**
2024.1	Mankan AK, Mankan N, de las Heras B, Ramkissoon SH, Bodriagova O, Vidal L, Grande E, Saini KS. **Bladder cancer, loss of Y-chromosome and new opportunities for immunotherapy.** *Advances in Therapy.* January 2024. https://doi.org/10.1007/s12325-023-02758-w
2024.2	Demetriou D, Lockhat Z, Brzozowski L, Saini KS, Dlamini Z, Hull R. **The convergence of radiology and genomics: Advancing breast cancer diagnosis with radiogenomics.** *Cancers.* March 2024. https://www.mdpi.com/2072-6694/16/5/1076
2024.3	Nesline MK, Subbiah V, Previs RA, Strickland KC, Ko H, DePietro P, Biorn MD, Cooper M, Wu N, Conroy J, Pabla S, Zhang S, Wallen ZD, Sathyan P, Saini KS, Eisenberg M, Caveney B, Severson EA, Ramkissoon S. **The impact of prior single-gene testing on comprehensive genomic profiling results for patients with non-small cell lung cancer.** *Oncology & Therapy.* March 2024. https://link.springer.com/article/10.1007/s40487-024-00270-x
2024.4	Vidal L, Dlamini Z, Qian S, Rishi P, Karmo M, Joglekar N, Abedin S, Previs RA, Orbegosa C, Joshi C, Azim H, Karkaria H, Harris M, Mehrotra R, Berraondo M, Werutski G, Gupta S, Niikura N, Chico I, Saini KS. **Equitable inclusion of diverse populations in oncology clinical trials: Deterrents and drivers.** *ESMO Open.* May 2024. https://www.esmoopen.com/article/S2059-7029(24)01141-4/fulltext
2024.5	Mankan AK, Shankar A, Limaye S, Ajaikumar BS, Nachane P, Singh N, Dawkhar S, Batra U, Bhosekar A, Ganguly S, Gawli P, Debnath K, Padalalu V, Reddy P, Sundaramoorthi S, Naveen KK, Bondarde S, Kumar P, Davis S, Ramkissoon S, Chacko RT, Vidal L, Chico I, Hegedus A, Gupta S, Saini KS. **Cancer trials ecosystem in India—ready for prime time?** *JCO Global Oncology.* June 2024. https://ascopubs.org/doi/full/10.1200/GO.23.00405
2024.6	Wallen ZD, Ko H, Nesline MK, Hastings SB, Strickland KC, Previs RA, Zhang S, Pabla S, Conroy J, Jackson JB, Saini KS, Jensen TJ, Eisenberg M, Caveney B, Sathyan P, Severson EA, Ramkissoon SH. **Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.** *Frontiers in Immunology.* June 2024. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1413956/full
2024.7	Perrone F, Pecci F, Maffezzoli M, Giudice GC, Cognigni V, Mazzaschi G, Cantini L, Santamaria L, Paoloni F, Rocchi MBL, Coriano M, Quaini F, Tiseo M, Saini KS, Berardi R, Buti S. **Differential impact of lipid profile according to NLR status in patients with advanced cancer treated with immunotherapy.** *Immunotherapy.* August 2024. https://doi.org/10.1080/1750743X.2024.2377953
2024.8	Quintana A, Saini KS, Vidal L, Loibl S, Curigliano G, Schmid P, Cortes J. **Use of immune checkpoint inhibitors in window-of-opportunity trials for triple negative breast cancer.** *ESMO Open.* October 2024. https://authors.elsevier.com/sd/article/S2059702924014832

Full list of published journals continued:

Number	Authors, Title, Journal
2024.9	Saini KS, Somara S, Ko HC, Thatai P, Quintana A, Wallen ZD, Green MF, Mehrotra R, McGuigan S, Pang L, Das S, Yadav K, Neric D, Cantini L, Joshi C, Iwamoto K, Dubbewar S, Vidal L, Chico I, Severson E, Lorini L, Badve S, Bossi P. **Biomarkers in head and neck squamous cell carcinoma: Unraveling the path to precision immunotherapy.** *Frontiers in Oncology*. October 2024. https://doi.org/10.3389/fonc.2024.1473706
2024.10	Strickland KC, Nesline MK, Previs RA, Ko H, Wallen ZD, Pabla S, Conroy JM, Sausen M, Saini KS, Cantini L, Jensen T, Caveney BJ, Eisenberg M, Severson EA, Ramkissoon SH. **Single gene testing and comprehensive genomic profiling in non-small cell lung cancer: A case series of divergent results from a large reference laboratory.** *Frontiers in Oncology.* October 2024. https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2024.1445668/full
2024.11	Bauchat A, Polishchuk V, Fabrizio VA, Brondon JE, Page KM, Driscoll TA, Martin PL, Mahadeo KM, Kurtzberg J, Prasad VK. **Safety and feasibility of umbilical cord blood transplantation in children with neuronal ceroid lipofuscinosis: A retrospective study.** *Stem Cells Transl Med.* October 2024. https://doi.org/10.1093/stcltm/szae080

2023	
Number	**Authors, Title, Journal**
2023.1	Filho PN, Albuquerque C, Pilon M, Debiasi M. **Immune checkpoint inhibitors in breast cancer: A narrative review.** *Oncology & Therapy.* March 2023. https://doi.org/10.1007/s40487-023-00224-9
2023.2	McDonald K, Seltzer E, Lu M, Gaisenband SD, Fletcher C, McLeroth P, Saini KS. **Quantifying the impact of the COVID-19 pandemic on clinical trial enrollment screening rates over time in 37 countries.** *Trials.* April 2023. https://doi.org/10.1186/s13063-023-07277-1
2023.3	Salifu I, Singh N, Berraondo M, Remon J, Salifu S, Severson E, Quintana A, Peiró S, Ramkissoon S, Vidal L, Chico I, Saini KS. **Antibody-drug conjugates, immune-checkpoint inhibitors and their combination in advanced non-small cell lung cancer.** *Cancer Treatment and Research Communications.* April 2023. https://doi.org/10.1016/j.ctarc.2023.100713
2023.4	Cantini L, Paoloni F, Pecci F, Spagnolo F, Genova C, Tanda ET, Aerts S, Rebuzzi SE, Fornarini G, Zoratto F, Fancelli S, Lupi A, Della Corte CM, Parisi A, Bennati C, Ortega C, Atzori F, Piovano PL, Orciuolo C, De Tursi M, Ghidini M, Botticelli A, Scagnoli S, Belluomini L, Leporati R, Veccia A, Di Giacomo AM, Festino L, Cortinovis D, Acquati M, Filetti M, Giusti R, Tucci M, Sergi MC, Garutti M, Puglisi F, Manglaviti S, Citarella F, Santoni M, Rijavec E, Lo Russo G, Santini D, Addeo A, Antonuzzo L, Indini A, Rocchi MBL, Cortellini A, Grossi F, Ascierto PA, Aerts JGJV, Berardi R. **Safety of extended interval dosing immune checkpoint inhibitors: A multicentre cohort study.** *Journal of National Cancer Institutes.* April 2023. https://doi.org/10.1093/jnci/djad061
2023.5	Severson E, Achyut BR, Nesline M, Pabla S, Previs RA, Kannan G, Chenn A, Zhang S, Klein R, Conroy J, Sausen M, Sathyan P, Saini KS, Ghosh A, Jensen TJ, Reddy P, Ramkissoon SH. **RNA sequencing identifies novel NRG1-fusions in solid tumors that lack co-occurring oncogenic drivers.** *The Journal of Molecular Diagnostics.* May 2023. https://doi.org/10.1016/j.jmoldx.2023.03.011
2023.6	Czajka-Francuz P, Prendes M, Mankan A, Quintana Á, Pabla S, Ramkissoon SH, Jensen TJ, Peiró S, Severson EA, Achyut BR, Vidal L, Poelman M, Saini KS. **Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy.** *Frontiers in Oncology.* June 2023. https://doi.org/10.3389/fonc.2023.1200646

Full list of published journals continued:

Number	Authors, Title, Journal
2023.7	Mankan AK, Czajka-Francuz P, Prendes M, Ramanan S, Koziej M, Vidal L, Saini KS. **Intracellular DNA sensing by neutrophils and amplification of the innate immune response.** *Frontiers in Immunology.* June 2023. https://doi.org/10.3389/fimmu.2023.1208137
2023.8	Bodriagova O, Previs RA, Gaba L, Shankar A, Vidal L, Saini KS. **Recent advances in gynecological malignancies: Focus on ASCO 2023.** *Oncology & Therapy.* September 2023. https://doi.org/10.1007/s40487-023-00244-5
2023.9	Pecci F, Cantini L, Cognigni V, Perrone F, Mazzaschi G, Agostinelli V, Mentrasti G, Favari E, Maffezzoli M, Cortellini A, Rossi F, Chiariotti R, Venanzi FM, Lo Russo G, Galli G, Proto C, Ganzinelli M, Tronconi F, Morgese F, Campolucci C, Moretti M, Vignini A, Tiseo M, Minari R, Rocchi MLB, Buti S, Berardi R. **Prognostic impact of blood lipid profile in patients with advanced solid tumors treated with immune checkpoint inhibitors: A multicenter cohort study.** *Oncologist.* October 2023. https://doi.org/10.1093/oncolo/oyad273
2023.10	Dlamini Z, Molefi T, Khanyile R, Mkhabele M, Damane B, Kokoua A, Bida M, Saini KS, Chauke-Malinga N, Luvhengo TE, Hull R. **From incidence to intervention: A comprehensive look at breast cancer in South Africa.** *Oncology & Therapy.* November 2023. https://doi.org/10.1007/s40487-023-00248-1
2023.11	Ko H, Previs R, Strickland K, Caveney B, Chiruzzi C, Eisenberg M, Severson E, Ramkissoon S, Saini KS. **Is HER2-low a new clinical entity or merely a biomarker for an antibody drug conjugate?** *Oncology & Therapy.* November 2023. https://doi.org/10.1007/s40487-023-00249-0
2023.12	Mishra AK, Gupta A, Dagar G, Das D, Chakraborty A, Haque S, Prasad CP, Singh A, Bhat AA, Macha MA, Benali M, Saini KS, Previs RA, Saini D, Saha D, Dutta P, Bhatnagar AR, Darswal M, Shankar A, Singh M. **CAR-T-cell therapy in multiple myeloma: B-cell maturation antigen (BCMA) and beyond.** *Vaccines.* November 2023. https://doi.org/10.3390/vaccines11111721
2023.13	Cantini L, Trapani D, Guidi L, Bielo LB, Scafetta R, Koziej M, Vidal L, Saini KS, Curigliano G. **Neoadjuvant therapy in hormone receptor-positive/HER2-negative breast cancer.** *Cancer Treatment Reviews.* December 2023. https://doi.org/10.1016/j.ctrv.2023.102669

2022	
Number	**Authors, Title, Journal**
2022.1	Franklin MR, Platero S, Saini KS, Curigliano G, Anderson S. **Immuno-oncology trends: Preclinical models, biomarkers, and clinical development.** *Journal of Immunotherapy for Cancer.* January 2022. https://doi.org/10.1136/jitc-2021-003231
2022.2	Saini KS, Svane IM, Juan M, Barlesi F, André F. **Manufacture of adoptive cell therapies at academic cancer centers: Scientific, safety and regulatory challenges.** *Annals of Oncology.* January 2022. https://doi.org/10.1016/j.annonc.2021.09.020
2022.3	De las Heras B, Daehnke A, Saini KS, Harris M, Morrison K, Aguilo A, Chico I, Vidal L, Myles J, Marcus R. **Decentralized clinical trials in oncology: Perspectives of oncologists and patients.** *Digital Health.* May 2022. https://doi.org/10.1177/20552076221099997

Full list of published journals continued:

2021	
Number	**Authors, Title, Journal**
2021.1	Saini KS, Twelves C. **Determining lines of therapy in patients with solid cancers: A proposed new systematic and comprehensive framework.** *British Journal of Cancer.* April 2021. https://www.nature.com/articles/s41416-021-01319-8
2021.2	Saini KS, Martins-Branco D, Tagliamento M, Vidal L, Singh N, Punie K, Saini ML, Chico I, Curigliano G, de Azambuja E, Lambertini M. **Emerging issues related to COVID-19 vaccination in patients with cancer.** *Oncology & Therapy.* May 2021. https://doi.org/10.1007/s40487-021-00157-1
2021.3	Moreno-Aspitia A, Holmes EM, Jackisch C, de Azambuja E, Boyle F, Hillman DW, Korde L, Fumagalli D, Izquierdo MA, McCullough AE, Wolff AC, Pritchard KI, Untch M, Guillaume S, Ewer MS, Shao Z, Sim SH, Aziz Z, Demetriou G, Mehta AO, Andersson M, Toi M, Lang I, Xu B, Smith IE, Barrios CH, Baselga J, Gelber RD, Piccart-Gebhart M; ALTTO Steering Committee and Investigators (Hilbers F, El-Abed S, Balta V, Schurmans C, Rosa DD, Saini KS, Filho OM, McConnell R, Paterson V, Campbell C, McFadden E, Paterson E, Kassab G). **Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D).** *European Journal of Cancer.* May 2021. https://doi.org/10.1016/j.ejca.2021.01.053
2021.4	Saini KS, Punie K, Twelves C, Bortini S, de Azambuja E, Anderson S, Criscitiello C, Awada A, Loi S. **Antibody-drug conjugates, immune-checkpoint inhibitors and their combination in breast cancer therapeutics.** *Expert Opinion in Biologic Therapy.* June 2021. https://doi.org/10.1080/14712598.2021.1936494
2021.5	Tagliamento M, Agostinetto E, Bruzzone M, Ceppi M, Saini KS, de Azambuja E, Punie K, Westphalen CB, Morgan G, Pronzato P, Del Mastro L, Poggio F, Lambertini M. **Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast malignancies: A systematic review and meta-analysis.** *Critical Reviews in Oncology and Hematology.* July 2021. https://doi.org/10.1016/j.critrevonc.2021.103365
2021.6	De Las Heras B, Bouyoucef-Cherchalli D, Reeve L, Reichl A, Mandarino D, Flach S, Vidal L, van Brummelen EMJ, Steeghs N. **Healthy volunteers in first-in-human oncology drug development for small molecules.** *British Journal of Clinical Pharmacology.* September 2021. https://doi.org/10.1111/bcp.15092

Full list of published journals continued:

2020	
Number	**Authors, Title, Journal**
2020.1	Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, Saini ML, Verma S, Leone M, Aftimos P, Curigliano G. **Effect of the COVID-19 pandemic on cancer treatment and research.** *Lancet Haematology.* June 2020. https://doi.org/10.1016/S2352-3026(20)30123-X
2020.2	Saini KS, Lanza C, Romano M, de Azambuja E, Cortes J, de Las Heras B, de Castro J, Lamba Saini M, Loibl S, Curigliano G, Twelves C, Leone M, Patnaik MM. **Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction and coagulopathy.** *British Journal of Cancer.* June 2020. https://doi.org/10.1038/s41416-020-0948-x
2020.3	De Las Heras B, Saini KS, Boyle F, Ades F, de Azambuja E, Bozovic-Spasojevic I, Romano M, Capelan M, Prasad R, Pattu P, Massard C, Portera C, Saini ML, Singh BP, Venkitaraman R, McNally R, Leone M, Grande E, Gupta S. **Cancer treatment and research during the COVID-19 pandemic: Experience of the first 6 months.** *Oncology & Therapy.* August 2020. https://doi.org/10.1007/s40487-020-00124-2
2020.4	Saini KS, de Las Heras B, Plummer R, Moreno V, Romano M, de Castro J, Aftimos P, Fredriksson J, Bhattacharyya GS, Olivo MS, Schiavon G, Punie K, Garcia-Foncillas J, Rogata E, Pfeiffer R, Orbegoso C, Morrison K, Curigliano G, Chin L, Saini ML, Rekdal Ø, Anderson S, Cortes J, Leone M, Dancey J, Twelves C, Awada A. **Reimagining global oncology clinical trials for the postpandemic era: A call to arms.** *JCO Global Oncology.* September 2020. https://doi.org/10.1200/GO.20.00346
2020.5	Saini KS, Tagliamento M, Lambertini M, McNally R, Romano M, Leone M, Curigliano G, de Azambuja E. **Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies.** *European Journal of Cancer.* November 2020. https://doi.org/10.1016/j.ejca.2020.08.011

LEARN MORE at fortrea.com

Fortrea

©2026 Fortrea Inc. All Rights Reserved.
IS_0063_FortreaPub_Onco_List2020-2026_1026_e2